Sergio Chimenti
YOU?
Author Swipe
View article: The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis
The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis Open
The novel nitrobenzoxadiazole (NBD) derivative MC3181 is endowed with remarkable therapeutic activity in mice bearing both sensitive and vemurafenibresistant human melanoma xenografts. Here, we report that subtoxic concentrations of this c…
View article: Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice Open
Objective To investigate the efficacy and safety outcomes of combination therapy used to optimize etanercept treatment in patients with psoriasis treated in real-life clinical practice. Methods Data from patients presenting with psoriasis,…
View article: From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience Open
Objective To evaluate results of the ‘pSORRIDI’ experience (which is a prevention campaign to evaluate the prevalence of comorbidities, multidisciplinary needs and appropriateness of the therapeutic approach for comorbidities) in patients …
View article: Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study Open
Aim To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis. Methods Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities a…
View article: Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis Open
Apremilast is an effective and well-tolerated option in treating moderate-to-severe plaque psoriasis. Its safety profile and the oral administration offer significant advantages in prescribing apremilast for the treatment of psoriasis, par…
View article: Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015)
Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015) Open
Though the recent introduction of new antipsoriatic agents has facilitated the management of long-term psoriasis, there is still a strong desire for alternative therapeutic options. Indeed, there remain unmet needs regarding safety and eff…